Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00511706
Other study ID # 206207-016
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 1, 2007
Est. completion date March 1, 2009

Study information

Verified date April 2019
Source Allergan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.


Recruitment information / eligibility

Status Completed
Enrollment 243
Est. completion date March 1, 2009
Est. primary completion date March 1, 2009
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria:

- 50 years of age or older with subfoveal choroidal neovascularization (CNV) (classic and/or occult) secondary to AMD

- Visual Acuity between 20/40 and 20/400 in the study eye

Exclusion Criteria:

- Any intraocular surgery within 3 months

- Glaucoma

- Cataract

- High eye pressure

- Uncontrolled systemic disease

Study Design


Intervention

Drug:
dexamethasone
Intravitreal injection of dexamethasone 700 µg at Day 1.
Biological:
ranibizumab
Ranibizumab 500 µg at day -30 and Day 7-14.
Other:
sham
Sham needle-less injection administered in the study eye at Day 1.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Allergan

Countries where clinical trial is conducted

United States,  Australia,  France,  Israel,  Italy,  Korea, Republic of,  New Zealand,  Portugal,  United Kingdom, 

References & Publications (1)

Kuppermann BD, Goldstein M, Maturi RK, Pollack A, Singer M, Tufail A, Weinberger D, Li XY, Liu CC, Lou J, Whitcup SM; Ozurdex® ERIE Study Group. Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial. Ophthalmologica. 2015;234(1):40-54. doi: 10.1159/000381865. Epub 2015 Jun 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Injection Free Interval The injection free interval was defined as the number of days between receiving the second ranibizumab injection (day 7 to 14) to the investigator's determination of eligibility to receive a third ranibizumab injection in the study eye. Week 1 to Week 25
Secondary Change From Baseline in the Best Corrected Visual Acuity (BCVA) at Week 25 BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Baseline, Week 25
Secondary Change From Baseline in the Mean Central Retinal Subfield Thickness at Week 25 as Assessed by Optical Coherence Tomography (OCT) in the Study Eye Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye after pupil dilation at baseline and Month 25. Baseline, Week 25
Secondary Change From Screening in the Area of Leakage From Choroidal Neovascularization (CNV) at Week 25 as Assessed by Fluorescein Angiography in the Study Eye Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA was performed on the study eye after dilation at Screening and Week 25. Screening (-Week 28), Week 25
See also
  Status Clinical Trial Phase
Completed NCT01908816 - An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Phase 3
Withdrawn NCT01666236 - Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy Phase 4
Completed NCT02015351 - Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study N/A
Completed NCT01175395 - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Terminated NCT00712491 - Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00533520 - Evaluation of Dosing Interval of Higher Doses of Ranibizumab Phase 4
Completed NCT00242580 - A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Phase 3
Completed NCT04075188 - Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid N/A
Not yet recruiting NCT05055973 - OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT.
Recruiting NCT00568191 - Stratus Versus Cirrus OCT in AMD N/A
Completed NCT01256632 - Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy N/A
Recruiting NCT00100087 - Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System Phase 1/Phase 2
Completed NCT04455399 - Time Efficiency Comparison of Two IntraVitreal Injection Techniques N/A
Terminated NCT02857894 - Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)
Not yet recruiting NCT02934841 - Conbercept in Choroidal Neovascularization Secondary to Uveitis Phase 2
Completed NCT01880788 - Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD N/A
Completed NCT00775411 - Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD) Phase 2
Completed NCT00604071 - Sensitivity of the Home Macular Perimeter (HMP) N/A
Completed NCT00406250 - Intravitreal Bevacizumab in Agioid Streaks Phase 1
Withdrawn NCT00403156 - Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Phase 1